In this special series of Translational Lung Cancer Research about “Immunotherapy in other thoracic malignancies and uncommon populations”, a group of renowned international specialists involved in the management of thoracic malignancies present a comprehensive and timely review of state-of-the-art of ICI in thoracic malignancies, discussing the lights and shadows of ICIs, either in under-represented patients with NSCLC in clinical trials, as well as the efficacy of ICIs in thoracic malignancies other than NSCLC.
Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?
Exploring the immune-checkpoint inhibitors’ efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease
Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis
First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis
Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations
The series “Immunotherapy in other thoracic malignancies and uncommon populations” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding. Jordi Remon and Benjamin Besse served as the unpaid Guest Editors for the series.